Aquestive Therapeutics (NASDAQ:AQST) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a report released on Saturday morning.

A number of other research analysts also recently commented on AQST. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Lake Street Capital set a $6.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.80.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $4.24 on Friday. The firm has a 50-day moving average of $4.08 and a 200-day moving average of $5.06. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $7.55. The company has a market cap of $517.45 million, a PE ratio of -5.44 and a beta of 1.54.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The firm had revenue of $13.02 million for the quarter, compared to the consensus estimate of $13.28 million. Analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Insider Buying and Selling at Aquestive Therapeutics

In other news, insider Sherry Korczynski sold 15,741 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $65,639.97. Following the transaction, the insider owned 241,117 shares in the company, valued at approximately $1,005,457.89. This trade represents a 6.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Melina Cioffi sold 25,311 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $105,546.87. Following the transaction, the senior vice president owned 274,867 shares in the company, valued at approximately $1,146,195.39. This trade represents a 8.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 395,690 shares of company stock worth $1,650,027 in the last ninety days. Insiders own 7.85% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new position in shares of Aquestive Therapeutics during the third quarter worth approximately $28,000. BNP Paribas Financial Markets increased its stake in shares of Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter worth about $33,000. Kestra Private Wealth Services LLC acquired a new stake in Aquestive Therapeutics in the 3rd quarter worth about $60,000. Finally, Lineweaver Wealth Advisors LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter worth about $65,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.